Paris, France, Monday, March 17, 2025, 7:30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that new scientific data and analyses on the gene therapy LUMEVOQ® will be presented at the 51st Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS) in Tucson, Arizona, USA (March 15-20, 2025).

 

Leading Leber Hereditary Optic Neuropathy (LHON) Key Opinion Leaders will share new data on predictive factors of response to LUMEVOQ® treatment; on a comparison of the treatment outcomes from idebenone and LUMEVOQ®; on real-world experience with LUMEVOQ®; and on long-term outcomes from bilateral treatment with the gene therapy.

 

Poster presentation: “Predictive Factors of Improved Final Visual Outcome in Patients with Leber Hereditary Optic Neuropathy Treated with Lenadogene Nolparvovec Gene Therapy”

  • Presenter: Robert C. Sergott, MD, Wills Eye Hospital, Philadelphia, USA
  • Poster Number 209
  • Time: Monday, March 17th, 2025, 5:00 pm – 6:00 pm (MDT)
  • Location: Arizona Ballroom 1-6

 

Poster presentation: “Efficacy of Lenadogene Nolparvovec Gene Therapy Versus Idebenone: Two Matched Adjusted Indirect Comparisons”

  • Presenter: Patrick Yu-Wai-Man, MD, PhD, University of Cambridge, Moorfields Eye Hospital, and the UCL Institute of Ophthalmology, UK
  • Poster Number 186
  • Time: Monday, March 17th, 2025, 6:00 pm – 7:00 pm (MDT)
  • Location: Arizona Ballroom 1-6

 

Poster presentation: “Efficacy and Safety of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy in the Real-Life Setting”

  • Presenter: Mark L. Moster, MD, Wills Eye Hospital, Philadelphia, USA
  • Poster Number 12
  • Time: Sunday, March 16th, 2025, 2:00 pm – 3:00 pm (MDT)
  • Location: Arizona Ballroom 1-6

 

Platform presentation: “Long-Term Outcomes of Bilateral Injection of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy”

  • Presenter: Nancy J. Newman, MD, Emory University School of Medicine, Atlanta, USA
  • Scientific Platform Session I
  • Time: Monday, March 17th, 2025, 11:45 am – 12:00 pm (MDT)
  • Location: Tucson Ballroom

Contacts